Trial Profile
A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Imiglucerase (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
- Sponsors ISU Abxis
- 16 Feb 2014 New trial record